Life sciences briefing: Monday, March 3 ,2008
TODAY’S HEADLINES:
InfraReDx takes $17M for arterial-plaque detection (VentureWire)
Cancer-drug developer Serenex sells out to Pfizer for undisclosed sum (release)
Life-sciences fund Longitude Capital raises $95M (VentureWire)
Hospital consultant Intercede Health names Gray Miller as CEO (release)
InfraReDx takes $17M for arterial-plaque detection – InfraReDx, a Burlington, Mass., developer of diagnostic systems that detect arterial plaque, raised $17 million in a third funding round, VentureWire reports. Sanderling Ventures led the round, joined by new and previous individual investors.
InfraReDx previously planned to… Continue Reading
Life sciences briefing: Monday, Aug. 27, 2007
Featured companies: Bravo Health, InfraReDx, MedAssets, Prestwick Pharmaceuticals
Prestwick Pharma raises $20M for neuro drugs — Specialty pharma Prestwick Pharmaceuticals, a Washington, D.C., firm that acquires cast-off drug candidates to treat neurological conditions, raised $20 million from existing investors, VentureWire reports (subscription required). Among those participating in the funding were Atlas Venture, Sofinnova Ventures, Vivo Ventures, Scale Venture Partners, Warburg Pincus and Pequot Ventures.
Prestwick said it raised the funds to acquire additional drug candidates. The company filed… Continue Reading
Life sciences briefing: Tuesday, Aug. 21, 2007
(UPDATED at 7:40pm PT: See below.)
Featured companies: Adnexus Therapeutics, BioForm Medical, Confirma, Cardiovascular Systems, Mirabilis Medica, Neuromed Pharmaceuticals, PlaCor, Seno Medical Instruments, Vibrynt
BioForm Medical files $115M IPO for “medical aesthetics” — BioForm Medical, a San Mateo, Calif., developer of wrinkle fillers and other products for cosmetic procedures, filed to raise $115 million in an initial offering. BioForm’s major customers are plastic surgeons and dermatologists.
BioForm, however, takes pains to describe itself differently on its Web site…. Continue Reading